Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Moleculin Biotech, Inc. (MBRX : NSDQ)
 
 • Company Description   
Moleculin Biotech, Inc. is a preclinical and clinical-stage pharmaceutical company which focused on the development of anti-cancer drug candidates. The company's lead product candidate is Annamycin, a Phase II clinical stage anthracycline for the treatment of relapsed or refractory acute myeloid leukemia. Moleculin Biotech, Inc. is based in Houston, TX.

Number of Employees: 21

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.31 Daily Weekly Monthly
20 Day Moving Average: 81,477 shares
Shares Outstanding: 28.58 (millions)
Market Capitalization: $37.44 (millions)
Beta: 1.83
52 Week High: $3.99
52 Week Low: $1.02
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -28.02% -21.19%
12 Week -7.09% 4.42%
Year To Date -29.57% -13.96%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
5300 MEMORIAL DRIVE SUITE 950
-
HOUSTON,TX 77007
USA
ph: 713-300-5160
fax: -
jsalierno@theruthgroup.com http://www.moleculin.com
 
 • General Corporate Information   
Officers
Walter V. Klemp - Chief Executive Officer and Chairman
Jonathan P. Foster - Executive Vice President and Chief Financial Offic
Robert George - Director
Michael Cannon - Director
John Climaco - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 60855D200
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/11/22
Share - Related Items
Shares Outstanding: 28.58
Most Recent Split Date: 2.00 (0.17:1)
Beta: 1.83
Market Capitalization: $37.44 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.25 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.01 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/11/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.52
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -20.00%
vs. Previous Quarter: -41.18%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -27.44
12/31/21 - -23.23
09/30/21 - -24.80
ROA
03/31/22 - -25.25
12/31/21 - -21.16
09/30/21 - -21.71
Current Ratio
03/31/22 - 13.91
12/31/21 - 20.02
09/30/21 - 21.08
Quick Ratio
03/31/22 - 13.91
12/31/21 - 20.02
09/30/21 - 21.08
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 2.54
12/31/21 - 2.76
09/30/21 - 2.85
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©